Evidance Medical Technologies Inc., Suzhou, China.
Department of Radiation Oncology, Rudong County People's Hospital, Rudong, China.
J Appl Clin Med Phys. 2021 Oct;22(10):120-135. doi: 10.1002/acm2.13405. Epub 2021 Aug 28.
This paper proposes a model for the angular dependency of MatriXX response and investigates whether MatriXX, with the angular-model-based approach can be applied to true composite dose verification for IMRT plans.
This model attributes the angular dependence of MatriXX response to dynamical translation of its effective measurement plane (EMP) due to the change of beam angle. Considering this mechanism, true composite dose verifications for IMRT plans specified in AAPM TG 119 report using both MatriXX and Gafchromic EBT3 films were undertook and compared to validate the applicability of MatriXX for patient specific QA of composite beam IMRT plans. Dose verifications using MatriXX with and without angular-model-based approach were performed.
MatriXX with angular-model-based approach achieved gamma passing rates with 3%/3 mm and 3%/2 mm criteria better than 98.3% and 98.1% respectively for true composite dose verification of plans in AAPM TG 119 report. The 3%/3 mm and 3%/2 mm gamma passing rates using MatriXX without angular-model-based approach ranged from 85.8% to 98.2% and from 81.3% to 96.5%, respectively. The p-values from the single sided paired t-test indicated no statistical difference between the passing rates from MatriXX with angular-model-based approach and from films, and significant difference between the passing rates from uncorrected MatriXX and from films.
The proposed model for angular dependent MatriXX response is necessary and effective. Dose verification using MatriXX with angular-model-based approach is acceptable for true composite beam IMRT plans with required accuracy to simplify patient specific QA.
本文提出了一种 MatriXX 响应角度依赖性模型,并研究了基于角度模型的 MatriXX 是否可应用于 IMRT 计划的真实复合剂量验证。
该模型将 MatriXX 响应的角度依赖性归因于由于射束角度的变化导致其有效测量平面(EMP)的动态平移。考虑到这种机制,使用 MatriXX 和 Gafchromic EBT3 胶片对 AAPM TG 119 报告中规定的 IMRT 计划进行了真实复合剂量验证,并进行了比较,以验证 MatriXX 对复合射束 IMRT 计划的患者特定 QA 的适用性。使用基于角度模型的方法和不使用角度模型的方法分别对 MatriXX 进行了剂量验证。
基于角度模型的方法的 MatriXX 在 AAPM TG 119 报告中,对于计划的真实复合剂量验证,分别以 3%/3mm 和 3%/2mm 标准,实现了伽马通过率大于 98.3%和 98.1%。不使用角度模型的方法的 MatriXX 的 3%/3mm 和 3%/2mm 伽马通过率范围分别为 85.8%至 98.2%和 81.3%至 96.5%。单边配对 t 检验的 p 值表明,基于角度模型的方法的 MatriXX 的通过率与胶片之间没有统计学差异,而未校正的 MatriXX 的通过率与胶片之间有显著差异。
提出的 MatriXX 响应角度依赖性模型是必要且有效的。使用基于角度模型的方法的 MatriXX 剂量验证对于具有所需精度的真实复合射束 IMRT 计划是可接受的,可简化患者特定 QA。